14.32
-0.42 (-2.85%)
| Previous Close | 14.74 |
| Open | 14.50 |
| Volume | 960,313 |
| Avg. Volume (3M) | 1,014,176 |
| Market Cap | 1,904,144,384 |
| Price / Earnings (TTM) | 6.92 |
| Price / Earnings (Forward) | 18.59 |
| Price / Sales | 7.55 |
| Price / Book | 5.11 |
| 52 Weeks Range | |
| Earnings Date | 11 May 2026 |
| Profit Margin | 16.11% |
| Operating Margin (TTM) | 37.43% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 24.20% |
| Total Debt/Equity (MRQ) | 22.25% |
| Current Ratio (MRQ) | 5.93 |
| Operating Cash Flow (TTM) | 64.29 M |
| Levered Free Cash Flow (TTM) | 47.49 M |
| Return on Assets (TTM) | 5.20% |
| Return on Equity (TTM) | 11.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Aurinia Pharmaceuticals Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 0.0 |
| Price Volatility | 1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 9.07% |
| % Held by Institutions | 47.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Nea Management Company, Llc | 31 Dec 2025 | 3,969,834 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| DONLEY MATTHEW MAXWELL | 14.17 | 14.21 | 17,399 | 244,913 |
| GREENLEAF PETER | 14.17 | 14.21 | 95,513 | 1,349,384 |
| KEENAN GREG | 14.17 | - | 40,586 | 575,104 |
| MILLER JOSEPH M | 14.17 | 14.21 | 19,718 | 277,904 |
| ROBERTSON STEPHEN P. | 14.17 | 14.21 | 22,565 | 318,285 |
| TANG KEVIN | 14.18 | - | 900,000 | 12,757,290 |
| Aggregate Net Quantity | 1,095,781 | |||
| Aggregate Net Value ($) | 15,522,879 | |||
| Aggregate Avg. Buy ($) | 14.17 | |||
| Aggregate Avg. Sell ($) | 14.21 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| TANG KEVIN | Director | 03 Mar 2026 | Buy (+) | 184,208 | 14.15 | 2,606,543 |
| GREENLEAF PETER | Officer | 02 Mar 2026 | Disposed (-) | 100,890 | 14.21 | 1,433,647 |
| MILLER JOSEPH M | Officer | 02 Mar 2026 | Disposed (-) | 37,511 | 14.21 | 533,031 |
| ROBERTSON STEPHEN P. | Officer | 02 Mar 2026 | Disposed (-) | 36,525 | 14.21 | 519,020 |
| DONLEY MATTHEW MAXWELL | Officer | 02 Mar 2026 | Disposed (-) | 40,761 | 14.21 | 579,214 |
| TANG KEVIN | Director | 02 Mar 2026 | Buy (+) | 199,353 | 14.21 | 2,832,806 |
| GREENLEAF PETER | Officer | 27 Feb 2026 | Acquired (+) | 196,403 | 14.17 | 2,783,031 |
| MILLER JOSEPH M | Officer | 27 Feb 2026 | Acquired (+) | 57,229 | 14.17 | 810,935 |
| KEENAN GREG | Officer | 27 Feb 2026 | Acquired (+) | 40,586 | 14.17 | 575,104 |
| ROBERTSON STEPHEN P. | Officer | 27 Feb 2026 | Acquired (+) | 59,090 | 14.17 | 837,305 |
| DONLEY MATTHEW MAXWELL | Officer | 27 Feb 2026 | Acquired (+) | 58,160 | 14.17 | 824,127 |
| TANG KEVIN | Director | 27 Feb 2026 | Buy (+) | 516,439 | 14.17 | 7,317,941 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |